Clinical Trial

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Name: Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma — clinical trial record (NCT07502287)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUAL-NK-NB

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma. After lymphodepletion, participants receive IV CAR-NK cells;Part A defines the RP2D and Part B estimates preliminary activity

Trial Details

NCT Number	NCT07502287
Lead Sponsor	Beijing Biotech
Conditions	Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
Enrollment	36 participants
Start Date	2026-03-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-06-17 (estimated)
Updated on ClinicalTrials.gov	2026-03-30